Inactive Instrument

Vitro Diagnostics, Inc.

VODG

US9285013036

Vitro Diagnostics, Inc. Appoints John R. Evans as Board of Director and Chief Financial Officer

May 30, 2017 at 12:45 pm EDT

On May 26, 2017, John R. Evans, was elected to serve as a member of the Board of Directors of Vitro Diagnostics, Inc. and appointed to the position of Chief Financial Officer.

Latest news about Vitro Diagnostics, Inc.

Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	May. 31	CI
Vitro Biopharma, Inc. announced that it has received $0.3 million in funding	May. 12	CI
Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	Apr. 10	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Jan. 29	CI
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes	Jan. 23	CI
Vitro Biopharma, Inc. announced that it has received $1 million in funding	Jan. 09	CI
Vitro Biopharma, Inc. announced a financing transaction	Nov. 15	CI
Vitro Biopharma, Inc. announced that it expects to receive $2 million in funding	Nov. 15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-08-28	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	23-07-12	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-13	CI
Vitro Biopharma, Inc. announced that it has received $0.325 million in funding	23-06-12	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	23-06-04	CI
Vitro Biopharma, Inc. announced that it has received $0.2 million in funding	23-04-13	CI
Vitro Biopharma, Inc. announced that it expects to receive CAD 0.2376 million in funding	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-01-30	CI
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	23-01-29	CI
Vitro Biopharma, Inc. amended terms of the transaction	23-01-22	CI
Vitro Biopharma, Inc. announced a financing transaction	23-01-05	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-11-03	CI
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million.	22-09-09	CI
Vitro Biopharma Inc. Auditor Raises 'Going Concern' Doubt	22-09-08	CI

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+6.53%	97.06B
SAMSUNG BIOLOGICS CO.,LTD.	+7.24%	41.54B
BIOGEN INC.	-8.49%	33.89B
UCB	+83.27%	29.78B
BIOMARIN PHARMACEUTICAL INC.	-12.97%	15.63B
INCYTE CORPORATION	-0.80%	13.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.43B
ALTEOGEN INC.	+173.60%	10.37B
SWEDISH ORPHAN BIOVITRUM AB	+4.64%	9.14B

Biopharmaceuticals